Search results for "Lymphatic"

showing 10 items of 1179 documents

[Cytomegalovirus infection in immunocompetent patients. Clinical and immunological considerations].

2012

Cytomegalovirus primary infection is considered dangerous for some kinds of patients: immunocompromised (HIV-infected and transplanted patients), newborns with congenital infection, and immunocompetent patients in critical condition. CMV infection is usually asymptomatic or only mildly symptomatic in immunocompetent hosts. We collected all cases of acute CMV infection that came to our attention during the period November 2009 - May 2011 to analyze their clinical features. Immunoenzymatic methods (ELISA) were used for the detection of specific IgM and IgG antibodies in every case. We observed 73 cases of acute CMV infection. The male-female ratio was 1.5/1. The average age was 36.4. All the …

AdultMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/17 - Malattie InfettiveAdolescentFeverCytomegalovirusEnzyme-Linked Immunosorbent AssayCitomegalovirus KirDiagnosis DifferentialRisk FactorsHumansChildLymphatic DiseasesAgedRetrospective StudiesAged 80 and overInfant NewbornInfantPharyngitisMiddle AgedImmunoglobulin MChild PreschoolImmunoglobulin GCytomegalovirus InfectionsFemaleImmunocompetenceBiomarkersLe infezioni in medicina
researchProduct

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002

Background Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Methods A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily pl…

AdultMaleSimeprevirmedicine.medical_specialtyGenotypeTaribavirinHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyPolyethylene GlycolsTelaprevirchemistry.chemical_compoundstomatognathic systemhemic and lymphatic diseasesInternal medicineBoceprevirRibavirinHumansMedicinebusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis C ChronicRecombinant Proteinsdigestive system diseasesInterleukin 28BchemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinesstherapeuticsmedicine.drugPeginterferon alfa-2a
researchProduct

A CTLA4high genotype is associated with myasthenia gravis in thymoma patients

2005

Myasthenia gravis (MG) in thymoma patients depends critically on intratumorous generation and export of mature autoreactive CD4+ T cells. Why non-MG thymomas fail to produce CD4+ T cells is unknown. We studied three single-nucleotide polymorphisms of the cytotoxic T-lymphocyte–associated antigen 4(CTLA4) gene in thymoma patients, nonthymoma early-onset MG patients, and control subjects. Surprisingly, the CTLA4high genotype +49A/A, which is protective against several autoimmune diseases, exerted a prominent predisposing effect to paraneoplastic MG in thymoma patients. The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4…

AdultMaleThymomaAdolescentGenotypeThymomaDisease Associationchemical and pharmacologic phenomenaPolymorphism Single NucleotidePathogenesis03 medical and health sciences0302 clinical medicineGene FrequencyAntigenAntigens CDhemic and lymphatic diseasesMyasthenia GravisGenotypeHumansMedicineCytotoxic T cellCTLA-4 AntigenChildGeneAgedDemography030304 developmental biology0303 health sciencesbusiness.industryThymus NeoplasmsMiddle Agedmedicine.diseaseAntigens DifferentiationMyasthenia gravis3. Good healthNeurologyImmunologyFemaleNeurology (clinical)business030215 immunologyAnnals of Neurology
researchProduct

Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma

2000

A consecutive series of 63 untreated patients undergoing surgical resection for stage I-IV gastric adenocarcinomas (GCs) has been prospectively studied. Our purpose was to analyze the predictive relevance of DNA ploidy, S-phase fraction (SPF), and tissue levels of lysosomal proteinases cathepsin D (CD), cathepsin B (CB), cathepsin L (CL), and urokinase-type plasminogen activator (uPA) and that of the intracellular cysteine proteinase inhibitor stefin A on clinical outcome. All of the patients taking part in this study were followed up for a median of 73 months. DNA aneuploidy was present in 71% of the cases (45/63), whereas 9% of these (4/45) showed multiclonality. Both DNA ploidy and SPF w…

AdultMaleTime FactorsAdenocarcinomaS PhasePredictive Value of TestsStomach NeoplasmsBiomarkers TumorAspartic Acid EndopeptidasesHumansNeoplasm Invasivenesshumancell cycle S phase; disease association; female; histopathology; human; lymph node metastasisAgedProbabilityPloidieslymph node metastasisdisease associationSerine EndopeptidasesDNA NeoplasmMiddle AgedPrognosisSurvival AnalysisCysteine Endopeptidasescell cycle S phaseLymphatic MetastasishistopathologyFemaleFollow-Up Studies
researchProduct

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment

2011

Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leukemia (CLL) cells to specific microenvironments. Here we have investigated whether the CX(3)CR1/CX(3)CL1 axis is involved in the interaction of CLL with their microenvironment. CLL cells from 52 patients expressed surface CX(3)CR1 and CX(3)CL1 and released constitutively soluble CX(3)CL1. One third of these were attracted in vitro by soluble CX(3)CL1. CX(3)CL1-induced phosphorylation of PI3K, Erk1/2, p38, Akt and Src was involved in induction of CLL chemotaxis. Leukemic B cells upregulated CXCR4 upon incubation with CX(3)CL1 and this was paralleled by increased chemotaxis to CXCL12. Akt phosp…

AdultMalechemokines; chronic lymphocytic leukemia (CLL); nurselike cells (NLCs); tumor microenvironmentCancer ResearchChemokineStromal cellChronic lymphocytic leukemiaCX3C Chemokine Receptor 1Antigens Differentiation MyelomonocyticchemokinesC-C chemokine receptor type 7Cell Communicationnurselike cells (NLCs)Chemokine receptorAntigens CDimmune system diseaseshemic and lymphatic diseaseschronic lymphocytic leukemia (CLL)medicineHumanstumor microenvironmentPhosphorylationAgedAged 80 and overTumor microenvironmentbiologyChemokine CX3CL1ChemistryChemotaxisHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellCX(3)CR1/CX(3)CL1 systemCX(3)CR1/CX(3)CL1 system; chronic lymphocytic leukemia.LeukemiaHaematopoiesisOncologychronic lymphocytic leukemia.Cancer researchbiology.proteinFemaleReceptors ChemokineLymph NodesProto-Oncogene Proteins c-aktSignal TransductionLeukemia
researchProduct

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

2007

Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous b…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentHemorrhagePostoperative HemorrhageGastroenterologyVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansProspective StudiesChildProspective cohort studyAgedAged 80 and overHemostasisBleeding episodesFactor VIIIbiologybusiness.industryHematologyMiddle Agedmedicine.diseaseSurgeryClinical trialvon Willebrand DiseasesCoagulationChild PreschoolHemostasisConcomitantbiology.proteinFemaleSafetybusinessJournal of Thrombosis and Haemostasis
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct